RHYTHM PHARMACEUTICALS, INC.
RYTM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RYTM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RYTM
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity, with its approved product IMCIVREE (setmelanotide) and a pipeline of clinical-stage candidates.
Key risk: Continued operating losses
BioSniper Score
Based on 6 of 6 signals
Market Cap
$7.35B
Cash Runway
113.5 moLead Asset
Bivamelagon (Phase 2)Next Catalyst
Phase3_Topline · Apr 16, 2027Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 16 clinical trials · 3 catalysts for RHYTHM PHARMACEUTICALS, INC..
Similar companies
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity, with its approved product IMCIVREE (setmelanotide) and a pipeline of clinical-stage candidates.
- Rhythm Pharmaceuticals has one approved product, IMCIVREE (setmelanotide), generating global net revenues of approximately $42 million as of January 2025 [sec · filed 2025-01-10].
- As of June 30, 2026, the company had an accumulated deficit of $1.5 billion and expects operating losses to continue for the foreseeable future [sec_mda · as of 2026-08-04].
- Latest reported financials (as of 2026-06-30) show cash & equivalents of $65.6M, total revenue of $71.3M, net income of -$49.3M, shareholders' equity of $139.1M, and total debt of $106.1M [sec].
- The company has wholly owned subsidiaries in the US, UK, Netherlands, France, Germany, Italy, Spain, Switzerland, Japan, and Canada [sec_mda · as of 2025-11-04].
- Rhythm Pharmaceuticals is conducting Phase 3 clinical trials for setmelanotide with topline data expected in 2027 and 2028 [upcoming catalysts].
What works
- Rhythm Pharmaceuticals has a commercially approved product, IMCIVREE, generating revenue and has built its own marketing and commercial sales infrastructure in the US and several European markets [sec_mda · as of 2026-02-26].
- The company has a global presence with subsidiaries in multiple countries, supporting potential international commercialization and regulatory activities [sec_mda · as of 2025-11-04].
- Rhythm Pharmaceuticals has a pipeline of clinical-stage candidates, with Phase 3 trials ongoing and topline data catalysts expected in 2027 and 2028 [upcoming catalysts].
What to weigh
- Rhythm Pharmaceuticals has incurred significant operating losses and negative cash flows since inception, with an accumulated deficit of $1.5 billion as of June 30, 2026 [sec_mda · as of 2026-08-04].
- The company expects operating losses to continue for the foreseeable future and may need substantial additional funding to support its research, development, and commercialization efforts [sec_mda · as of 2026-08-04].
- Rhythm Pharmaceuticals faces risks common to commercial-stage biotech companies, including competition, regulatory approvals, and dependence on key personnel and proprietary technology [sec_mda · as of 2025-11-04].
From the filings
Quoted directly from source documents.
The company has an accumulated deficit of $1.5 billion as of June 30, 2026.
“As of June 30, 2026, the Company had an accumulated deficit of $ 1.5 billion.”
SEC MD&A · August 4, 2026
The company announced preliminary unaudited net revenues from global sales of IMCIVREE of approximately $42 million.
“On January 10, 2025, the Company announced preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 milli”
SEC filings · January 10, 2025
The company expects operating losses to continue for the foreseeable future.
“While the Company is generating product revenue, management expects operating losses to continue for the foreseeable future.”
SEC MD&A · August 4, 2026
The company has wholly owned subsidiaries in multiple countries.
“The Company has wholly owned subsidiaries in the US, the United Kingdom, the Netherlands, France, Germany, Italy, Spain, Switzerland, Japan and Canada.”
SEC MD&A · November 4, 2025
Catalyst timeline
- 2027-04-16 · Phase3_Topline — Phase 3 Topline: A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of — Topline data from a Phase 3 trial of setmelanotide; results will inform efficacy and safety profile.
- 2028-03-13 · Phase3_Topline — Phase 3 Topline: A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of — Topline data from another Phase 3 trial of setmelanotide; results will inform efficacy and safety profile.
- 2034-07-04 · Patent_Expiry · IMCIVREE — Patent/Exclusivity Expiry: IMCIVREE — Patent or exclusivity expiry for IMCIVREE, which could allow generic competition.
Risks & what to watch (3)›
Key risks
- Continued operating losses — The company has an accumulated deficit of $1.5B and expects losses to continue, requiring additional funding [sec_mda · as of 2026-08-04].
- Need for additional capital — The company may need substantial funding to support R&D and commercialization; failure to raise capital could delay programs [sec_mda · as of 2026-02-26].
- Clinical and regulatory risks — The company faces risks from clinical trials, regulatory approvals, and competition in the biotech industry [sec_mda · as of 2025-11-04].
What to watch
- Phase 3 topline data for setmelanotide expected in 2027 and 2028 [upcoming catalysts].
- Cash runway and ability to secure additional financing given ongoing operating losses [sec_mda · as of 2026-08-04].
- Commercial performance of IMCIVREE and expansion into international markets [sec_mda · as of 2026-02-26].
- Patent expiry for IMCIVREE in 2034, which could impact long-term revenue [upcoming catalysts].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run RHYTHM PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RHYTHM PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
113.5 months
D/E 2.14 · 0% dilution
Lead: Approved
4 candidates
3 upcoming, next in ~229d
0 buys · 15 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
286
Total value held
$6.86B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 6,666,837 | $579.8M |
| blackrock, inc. | 6,237,151 | $542.4M |
| vanguard capital management llc | 5,935,650 | $516.2M |
| baker bros. advisors lp | 5,604,483 | $487.4M |
| perceptive advisors llc | 4,747,590 | $412.9M |
| primecap management co/ca/ | 3,417,509 | $297.2M |
| vanguard portfolio management llc | 3,040,718 | $264.5M |
| state street corp | 2,271,851 | $197.6M |
| goldman sachs group inc | 1,965,432 | $170.9M |
| westfield capital management co lp | 1,929,123 | $167.8M |
Showing top 10 of 286 institutional holders of RHYTHM PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 14.2%
- Days to cover
- 6.9
- Shares short
- 7,624,913
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RYTM short interestGovernance
Frequently asked questions
What is the AI investment thesis for RHYTHM PHARMACEUTICALS, INC.?
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity, with its approved product IMCIVREE (setmelanotide) and a pipeline of clinical-stage candidates.
What is RHYTHM PHARMACEUTICALS, INC.'s lead drug candidate?
RHYTHM PHARMACEUTICALS, INC.'s most advanced tracked candidate is Bivamelagon (Phase 2) for Hypothalamic Obesity.
What is RHYTHM PHARMACEUTICALS, INC.'s next catalyst?
RHYTHM PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of" — expected April 16, 2027.
Who is the CEO of RHYTHM PHARMACEUTICALS, INC.?
Dr. David P. Meeker M.D. is the chief executive officer of RHYTHM PHARMACEUTICALS, INC. (RYTM).
Where is RHYTHM PHARMACEUTICALS, INC. headquartered?
RHYTHM PHARMACEUTICALS, INC. (RYTM) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.